JP2001514181A - Gaba脳レセプタリガンドとしての置換4−オキソ−ナフチリジン−3−カルボキサミド - Google Patents

Gaba脳レセプタリガンドとしての置換4−オキソ−ナフチリジン−3−カルボキサミド

Info

Publication number
JP2001514181A
JP2001514181A JP2000507675A JP2000507675A JP2001514181A JP 2001514181 A JP2001514181 A JP 2001514181A JP 2000507675 A JP2000507675 A JP 2000507675A JP 2000507675 A JP2000507675 A JP 2000507675A JP 2001514181 A JP2001514181 A JP 2001514181A
Authority
JP
Japan
Prior art keywords
oxo
naphthyridine
carboxamide
tetrahydro
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000507675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001514181A5 (pt
Inventor
パメラ アルボー、
ロバート ダブリュー. デシモン、
ガン リュー、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of JP2001514181A publication Critical patent/JP2001514181A/ja
Publication of JP2001514181A5 publication Critical patent/JP2001514181A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000507675A 1997-08-25 1998-08-24 Gaba脳レセプタリガンドとしての置換4−オキソ−ナフチリジン−3−カルボキサミド Pending JP2001514181A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91818097A 1997-08-25 1997-08-25
US08/918,180 1997-08-25
PCT/US1998/017513 WO1999010347A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Publications (2)

Publication Number Publication Date
JP2001514181A true JP2001514181A (ja) 2001-09-11
JP2001514181A5 JP2001514181A5 (pt) 2006-01-05

Family

ID=25439933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000507675A Pending JP2001514181A (ja) 1997-08-25 1998-08-24 Gaba脳レセプタリガンドとしての置換4−オキソ−ナフチリジン−3−カルボキサミド

Country Status (24)

Country Link
EP (1) EP1007526A1 (pt)
JP (1) JP2001514181A (pt)
KR (1) KR20010023313A (pt)
CN (1) CN1268136A (pt)
AP (1) AP2000001742A0 (pt)
AU (1) AU753800B2 (pt)
BG (1) BG104192A (pt)
BR (1) BR9811362A (pt)
CA (1) CA2301599C (pt)
EG (1) EG21717A (pt)
HU (1) HUP0003258A3 (pt)
IL (1) IL134291A0 (pt)
IS (1) IS5382A (pt)
LV (1) LV12539B (pt)
NO (1) NO20000822L (pt)
NZ (1) NZ502548A (pt)
OA (1) OA11293A (pt)
PE (1) PE130999A1 (pt)
PL (1) PL338783A1 (pt)
SI (1) SI20270A (pt)
SK (1) SK2162000A3 (pt)
TW (1) TW574221B (pt)
WO (1) WO1999010347A1 (pt)
YU (1) YU10500A (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510314A (ja) * 2006-11-22 2010-04-02 シーサイド セラピューティクス,エルエルシー 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法
JP2013189453A (ja) * 2006-10-16 2013-09-26 Bionomics Ltd 新規な抗不安薬化合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4818000A (en) * 1999-05-06 2000-11-21 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
WO2000071528A1 (en) * 1999-05-25 2000-11-30 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
ES2287170T3 (es) 2000-10-12 2007-12-16 MERCK & CO., INC. Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa.
CA2425625A1 (en) 2000-10-12 2002-07-18 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
DE60138635D1 (de) 2000-10-12 2009-06-18 Merck & Co Inc Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
SK10752003A3 (sk) * 2001-03-01 2004-08-03 Pfizer Products Inc. Použitie inverzných agonistov GABAA v kombinácii s parciálnymi agonistami receptora nikotínu, estrogénom, selektívnymi modulátormi estrogénu alebo vitamínom E pri liečení kognitívnych porúch
AR036256A1 (es) 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
DE60315796T2 (de) 2002-01-17 2008-06-05 Merck & Co., Inc. Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
JP4494020B2 (ja) 2002-03-15 2010-06-30 メルク・シャープ・エンド・ドーム・コーポレイション Hivインテグラーゼ阻害剤として有用なn−(置換ベンジル)−8−ヒドロキシ−1,6−ナフチリジン−7−カルボキサミド
WO2004106336A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides
WO2004106334A2 (en) * 2003-05-28 2004-12-09 Pfizer Products Inc. Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204162A1 (es) * 1972-05-08 1975-11-28 Yamanouchi Pharma Co Ltd Proceso para la preparacion de derivados de ampicilina
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
DD295360A5 (de) * 1987-07-03 1991-10-31 Akad Wissenschaften Verfahren zur Herstellung von aktivierten Carbonsäureestern
DD279875A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von aktivierten carbonsaeureestern
DD279887A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013189453A (ja) * 2006-10-16 2013-09-26 Bionomics Ltd 新規な抗不安薬化合物
JP2015155444A (ja) * 2006-10-16 2015-08-27 バイオノミクス リミテッド 新規な抗不安薬化合物
JP2010510314A (ja) * 2006-11-22 2010-04-02 シーサイド セラピューティクス,エルエルシー 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法

Also Published As

Publication number Publication date
NO20000822L (no) 2000-04-13
EP1007526A1 (en) 2000-06-14
AU753800B2 (en) 2002-10-31
PL338783A1 (en) 2000-11-20
BR9811362A (pt) 2000-08-22
YU10500A (sh) 2002-10-18
LV12539A (en) 2000-10-20
AP2000001742A0 (en) 2000-02-24
NO20000822D0 (no) 2000-02-18
WO1999010347A1 (en) 1999-03-04
IL134291A0 (en) 2001-04-30
BG104192A (en) 2001-05-31
LV12539B (en) 2001-01-20
SI20270A (sl) 2000-12-31
CA2301599C (en) 2003-03-25
SK2162000A3 (en) 2001-03-12
CA2301599A1 (en) 1999-03-04
KR20010023313A (ko) 2001-03-26
HUP0003258A2 (en) 2001-03-28
IS5382A (is) 2000-02-22
PE130999A1 (es) 1999-12-16
TW574221B (en) 2004-02-01
CN1268136A (zh) 2000-09-27
NZ502548A (en) 2002-06-28
HUP0003258A3 (en) 2001-05-28
AU9117398A (en) 1999-03-16
OA11293A (en) 2002-11-19
EG21717A (en) 2002-02-27

Similar Documents

Publication Publication Date Title
US6646124B2 (en) Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
US6103903A (en) 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
JP2001514181A (ja) Gaba脳レセプタリガンドとしての置換4−オキソ−ナフチリジン−3−カルボキサミド
US5908932A (en) Certain pyrroloquinolinones; a new class of GABA brain receptor
US6423711B1 (en) Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands
US6156898A (en) Substituted 1,4-dihydro-4-oxonicotinic carboxamides; GABA brain receptor ligands
US5840888A (en) Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US6177569B1 (en) Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
US6194427B1 (en) Substituted cycloalkyl-4-Oxonicotinic carboxamides; gaba brain receptor ligands
US6380210B1 (en) Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
JP2002541151A (ja) アリールおよびヘテロアリール縮合アミノアルキル−イミダゾール誘導体:GABAa受容体の選択的修飾物質
US5610299A (en) Certain aryl substituted imidazopyrazinones; a new class of GABA brain receptor ligands
EP1107966B1 (en) Oxo-pyridoimidazole-carboxamides: gaba brain receptor ligands
US6627624B1 (en) Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
MXPA00001598A (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
MXPA01001991A (en) Oxo-pyridoimidazole-carboxamides:gaba brain receptor ligands
MXPA00008364A (en) Substituted cycloalkyl-4-oxonicotinic carboxamides;gaba brain receptor ligands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090825

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100720